IPO - Alopexx, Inc.

Form Type: S-1/A

Filing Date: 2025-02-25

Corporate Action: Ipo

Type: New

Accession Number: 000121390025016709

Filing Summary: This document is an amendment to the registration statement for Alopexx, Inc., outlining the offering of 2,400,000 shares of common stock in an initial public offering (IPO) through the NYSE American under the symbol 'ALPX'. The anticipated initial offering price is $5.00 per share, aiming for gross proceeds of no less than $12,000,000. Alopexx is a clinical-stage biotechnology firm focusing on immune therapeutics for various infections targeting the antigen poly N-acetyl glucosamine (PNAG). The company has completed trials for its vaccine AV0328 and monoclonal antibody F598, both showing promising efficacy and safety results. The document emphasizes the strategic focus on creating broad-spectrum therapeutics while planning collaborations for advanced trials, including with Europe's largest healthcare system. It also details risk factors, financial condition, and marketing strategies relevant to potential investors.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: Update

Accession Number: 000183988225001330

Filing Summary: Alopexx, Inc. has filed an amendment (S-1/A) to its registration statement under the Securities Act of 1933, indicating a proposed initial public offering of common stock. The registration incorporates two prospectuses: a Public Offering Prospectus for 2,400,000 shares and a Resale Prospectus for 300,000 shares by a selling stockholder. The anticipated initial public offering price is $5.00 per share, with expected gross proceeds of at least $12 million. The company is seeking to list on the NYSE American under the symbol 'ALPX'. The registration is subject to SEC approval, and this follows prior filings leading up to the company's public offering. Alopexx is focused on developing immune therapeutics targeting poly N-acetyl glucosamine (PNAG) to combat infections, with products like the vaccine AV0328 and monoclonal antibody F598 showing promise in clinical trials. The firm positions itself as a smaller reporting company and an emerging growth company, indicating compliance with reduced public company obligations that apply under these classifications.

Document Link: View Document